SAB Biotherapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

SABS$3.07-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes In Stockholders’ Equity

Common stock · Series B Preferred Stock · Series A Preferred Stock · Treasury Stock
Shares · Amount · Shares · Amount · Shares · Amount · AdditionalPaid-In Capital · Shares · Amount · AccumulatedDeficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’Equity
Balance at December 31, 2025	47,664,564	$5	638,558	$—		28,380		$—		$267,719		(54,665)		$(5,521)	$(110,895)	$187	$151,495
Stock-based compensation	—	—	—	—		—		—		5,460		—		—	—	—	5,460
Issuance of common stock for exercise of stock options	39,083	—			—		—		113	—	—		—	—	113
Issuance of common stock pursuant to vesting of restricted stock units	3,017	—	—	—		—		—		—		—		—	—	—	—
Payment of taxes withheld on issuance of restricted stock units	—	—	—	—		—		—		(5)		—		—	—	—	(5)
Conversion of Series B Preferred Stock into common shares	6,767,900	1	(67,679)	—		—		—		(1)		—		—	—	—	—
Exercise of Enrollment Date Warrants into Series B Preferred Stock	—	—	17,000	—		—		—		2,975		—		—	—	—	2,975
Issuance of common stock and prefunded warrants under the March 2026 Public Offering, net of issuance costs	19,324,677	2	—	—		—		—		79,249		—		—	—	—	79,251
Issuance of common stock under the March 2026 Public Offering Underwriters' Option, net of issuance costs	2,000,000	—	—	—		—		—		7,238		—		—	—	—	7,238
Net loss	—	—	—	—		—		—		—		—		—	(18,869)	—	(18,869)
Foreign currency translation	—	—	—	—		—		—		—		—		—	—	137	137
Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment	—	—	—	—		—		—		—		—		—	—	(547)	(547)
Balance at March 31, 2026	75,799,241	$8	587,879	$—		28,380		$—		$362,748		(54,665)		$(5,521)	$(129,764)	$(223)	$227,248
Stock-based compensation	—	—	—	—		—		—		7,247		—		—	—	—	7,247
Issuance of common stock for exercise of stock options	25,000	—			—		—		42	—	—		—	—	42
Issuance of common stock pursuant to vesting of restricted stock units	3,016	—	—	—		—		—		—		—		—	—	—	—
Payment of taxes withheld on issuance of restricted stock units	—	—	—	—		—		—		(4)		—		—	—	—	(4)
Conversion of Series B Preferred Stock into common shares	7,035,000	—	(70,350)	—		—		—		—		—		—	—	—	—
Exercise of Enrollment Date Warrants into Series B Preferred Stock	—	—	3,100	—		—		—		543		—		—	—	—	543
Exercise of Release Date Warrants into Series B Preferred Stock	—	—	2,000	—		—		—		438		—		—	—	—	438
Issuance of common stock under the March 2026 Public Offering Underwriters' Option, net of issuance costs	610,188	—	—	—		—		—		2,208		—		—	—	—	2,208
Issuance of common stock as consideration for professional services	75,288	—	—	—		—		—		261		—		—	—	—	261
Net loss	—	—	—	—		—		—		—		—		—	(22,491)	—	(22,491)
Foreign currency translation	—	—	—	—		—		—		—		—		—	—	10	10
Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment	—	—	—	—		—		—		—		—		—	—	(717)	(717)
Balance at June 30, 2026	83,547,733	$8	522,629	$—		28,380		$—		$373,483		(54,665)		$(5,521)	$(152,255)	$(930)	$214,785

Condensed Consolidated Statements of Changes In Stockholders’ Equity

Common stock · Series B Preferred Stock · Series A Preferred Stock · Treasury Stock
	Shares	Amount	Shares	Amount	Shares	Amount	AdditionalPaid-In Capital	Shares	Amount	AccumulatedDeficit	Accumulated Other Comprehensive Income (Loss)	Total Stockholders’Equity
Balance at December 31, 2024	9,343,533	$1	—	$—	42,019	$—	$155,794	(54,665)	$(5,521)	$(124,169)	$(135)	$25,970
Stock-based compensation	—	—	—	—	—	—	613	—	—	—	—	613
Issuance of common stock pursuant to vesting of restricted stock units	2,829	—	—	—	—	—	—	—	—	—	—	—
Payment of taxes withheld on issuance of restricted stock units	—	—	—	—	—	—	(2)	—	—	—	—	(2)
Net loss	—	—	—	—	—	—	—	—	—	(5,197)	—	(5,197)
Foreign currency translation	—	—	—	—	—	—	—	—	—	—	25	25
Unrealized loss, change in fair value of available-for-sale securities	—	—	—	—	—	—	—	—	—	—	(1)	(1)
Balance at March 31, 2025	9,346,362	$1	—	$—	42,019	$—	$156,405	(54,665)	$(5,521)	$(129,366)	$(111)	$21,408
Stock-based compensation	—	—	—	—	—	—	627	—	—	—	—	627
Net loss	—	—	—	—	—	—	—	—	—	(10,114)	—	(10,114)
Foreign currency translation	—	—	—	—	—	—	—	—	—	—	95	95
Unrealized gain, change in fair value of available-for-sale securities	—	—	—	—	—	—	—	—	—	—	—	—
Balance at June 30, 2025	9,346,362	1	—	$—	42,019	—	157,032	(54,665)	(5,521)	(139,480)	(16)	12,016

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.